Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Kuendgen A, et al. Among authors: list a. Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29. Leukemia. 2021. PMID: 32595214 Free PMC article.
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.
Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P, Hamblin T, Hellstrom-Lindberg E, List A, Mufti G, Neuwirtova R, Ohyashiki K, Oscier D, Sanz G, Sanz M, Willman C. Greenberg P, et al. Among authors: list a. J Clin Oncol. 2000 Oct 1;18(19):3447-52. doi: 10.1200/JCO.2000.18.19.3447. J Clin Oncol. 2000. PMID: 11013289 No abstract available.
Myelodysplastic syndromes.
List AF, Vardiman J, Issa JP, DeWitte TM. List AF, et al. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561689 Review.
Alternative treatments for myelodysplastic syndromes.
Sekeres M, List A. Sekeres M, et al. Among authors: list a. Semin Hematol. 2005 Jul;42(3 Suppl 2):S32-7. doi: 10.1053/j.seminhematol.2005.05.008. Semin Hematol. 2005. PMID: 16015503 Review.
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. Giles FJ, et al. Leuk Res. 2006 Jul;30(7):801-11. doi: 10.1016/j.leukres.2005.10.024. Epub 2005 Dec 5. Leuk Res. 2006. PMID: 16332390 Clinical Trial.
495 results